Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €0.64 EUR
Change Today +0.014 / 2.24%
Volume 315.1K
ECR On Other Exchanges
As of 11:38 AM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

ercros sa (ECR) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/15 - €0.77
52 Week Low
12/31/14 - €0.38
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ERCROS SA (ECR)

Related News

No related news articles were found.

ercros sa (ECR) Related Businessweek News

No Related Businessweek News Found

ercros sa (ECR) Details

Ercros, S.A. manufactures and sells basic chemicals and plastics, intermediate chemicals, and pharmaceuticals in Spain. The company’s Basic Chemicals division produces ammonia, caustic potash and soda, chlorine, Chloroisocyanurates, dicalcium phosphate, hydrochloric acid, hydrogen peroxide, and potassium carbonate, as well as sodium chlorate, chloride, chlorite, and hypochlorite. This segment’s products are used as intermediates in other industrial processes to purify and treat drinking and waste water; treat and maintain swimming pool water; bleach fabrics and paper; produce solvents, detergents, and strippers; manufacture printing inks and colouring; produce compound feed and in cooling equipment; and others. The company’s Plastics division offers dichloroethane, polyvinyl chloride (PVC) compounds, vinyl chloride monomer (VCM), and vinyl polychloride for use in VCM and PVC manufacturing and construction applications. Its Intermediate Chemicals division provides formaldehyde, glues and resins, moulding compounds, paraformaldehyde, pentaerythritol and dipentaerythritol, and sodium formate for derivatives manufacturing, wood industry, electrotechnics, resins, paints, and tanning industry applications. The company’s Pharmaceuticals division focuses on the production of raw materials and intermediate pharmaceutical products of antibiotics, hypercholesterolemia, anti-ulcer, and anti-fungal products. Its products include amlodipine besylate, azithromycin, clarithromycin, erythromycins, famotidine, and fusidic acid, as well as fosfomycin calcium, sodium, and trometamol for use in antibiotic and skin infections. The company exports its products to approximately 128 countries. Ercros, S.A. was founded in 1817 and is headquartered in Barcelona, Spain.

Founded in 1817

ercros sa (ECR) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €465.1K
Compensation as of Fiscal Year 2014.

ercros sa (ECR) Key Developments

Ercros, S.A., Annual General Meeting, Jun 29, 2015

Ercros, S.A., Annual General Meeting, Jun 29, 2015., at 12:00 Central European Standard Time. Location: Mutual Gene Insurance Entenza street, 325-335.

Ercros Reports Consolidated Earnings Results for the First Quarter of 2015

Ercros reported consolidated earnings results for the first quarter of 2015. For the quarter, the company reported profit of EUR 0.40 million compared to a loss of EUR 2.78 million incurred in the same period of 2014, a difference of EUR 3.18 million. Turnover was EUR 152.41 million against EUR 149.69 million a year ago. Income was EUR 150.35 million against EUR 147.03 million a year ago. EBITDA was EUR 5.26 million against EUR 4.42 million a year ago. EBIT was EUR 0.28 million against EUR 0.23 million a year ago. Profit before tax was EUR 0.39 million against loss before tax of EUR 2.78 million a year ago.

Ercros, S.A. Reports Financial Results for the Year 2014; Provides Financial Outlook for 2015

Ercros, S.A. reported financial results for the year 2014. For the year, total income was EUR 606.80 million against EUR 624.21 million for the last year. Ebitda was EUR 14.44 million against EUR 28.45 million for the last year. LBIT was EUR 5.01 million against EUR 9.14 million for the last year. Loss before tax was EUR 12.51 million against EUR 1.00 million for the last year. Loss for the year was EUR 6.29 million against EUR 3.75 million for the last year. In 2014, the turnover of Ercros amounted to EUR 603.67 million, 3.4% lower than that achieved in 2013. The main reason behind this decline is the lower price for caustic soda and PVC, in line with the observed downward trend in commodities prices. The turnover for the fourth quarter was also affected by a substantial cut in the compensation received for the interruptibility services provided by the company to the electricity system operator and by a lower production in some plants due to the force majeure declared by one of the leading suppliers and to scheduled maintenance activities. Non-recurrent items have amounted to EUR 4.93 million against EUR 0.57 million in 2013, while ebitda linked to the ordinary activities of the company has reached EUR 19.37 million compared to EUR 27.88 million in the previous year. The financial loss has amounted to EUR 7.50 million, compared to EUR 10.14 million in the previous year, as a result of interest rates reduction and less indebtedness. As at December 31, 2014, the net financial debt stood at EUR 99.52 million, EUR 24.32 million less than in 2013 after the repayment of most of the financial debt with suppliers and other financing facilities. To calculate the net financial debt, the company has deducted all the deposits used as collateral of debts. Ercros considers that what has happened in the fourth quarter of 2014 has been due to extraordinary events mostly beyond the control of the company, which need not be repeated. For the outlook of 2015, the company announced that it is much more promising as a result of the continuing recovery of the economic activity already seen in 2014. There are several facts that give support to the expected improvement of the results: the strengthening of the dollar against the euro, which is already having a significant impact on the overall activity of the company in the first months of the year and, especially in export oriented businesses, such as intermediate chemicals and pharmaceuticals, and the dramatic reduction in oil prices, which impact the price of natural gas. On the other side, it should note the risk of higher electricity prices fixed by the market in daily auctions, and the lower compensation for the interruptibility services.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ECR:SM €0.64 EUR +0.014

ECR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ECR.
View Industry Companies

Industry Analysis


Industry Average

Valuation ECR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.1x
Price/Book 0.4x
Price/Cash Flow 4.5x
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ERCROS SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at